All In Biotech

Drug Trial Radar · NCT03823287

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (TENAYA)

Last checked: Nov 20, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 671 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

671

Actual

Start

Feb 19, 2019

Primary completion

Oct 26, 2020

Study completion Jan 18, 2022

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).

Conditions

  • Wet Macular Degeneration

Interventions

  • FaricimabDrug

    Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.

  • AfliberceptDrug

    Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).

  • Sham ProcedureProcedure

    The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48Time frame: From Baseline through Week 48

Locations

161 sites in 15 countries. Site status is shown where the registry gives one.

  • Retinal Research Institute, LLC

    Phoenix, Arizona

  • Barnet Dulaney Perkins Eye Center

    Phoenix, Arizona

  • Retina Associates Southwest PC

    Tucson, Arizona

  • Retinal Diagnostic Center

    Campbell, California

  • The Retina Partners

    Encino, California

  • Jacobs Retina center at the Shiley eye Institute UCSD

    La Jolla, California

  • South Coast Retina Center

    Long Beach, California

  • Southern CA Desert Retina Cons

    Palm Desert, California

  • California Eye Specialists Medical group Inc.

    Pasadena, California

  • Retina Consultants, San Diego

    Poway, California

  • Retina Consultants of Southern California

    Redlands, California

  • University of California, Davis, Eye Center

    Sacramento, California

  • Retina Consultants of Southern

    Colorado Springs, Colorado

  • Retina Group of New England

    New London, Connecticut

  • Rand Eye

    Deerfield Beach, Florida

  • Florida Eye Associates

    Melbourne, Florida

  • Retina Specialty Institute

    Pensacola, Florida

  • Fort Lauderdale Eye Institute

    Plantation, Florida

  • Retina Vitreous Assoc of FL

    St. Petersburg, Florida

  • Northwestern Medical Group/Northwestern University

    Chicago, Illinois

  • Retina Associates

    Lenexa, Kansas

  • Johns Hopkins Med

    Baltimore, Maryland

  • Retina Group of Washington

    Chevy Chase, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Associated Retinal Consultants

    Grand Rapids, Michigan

  • Midwest Vision Research Foundation

    Chesterfield, Missouri

  • Retina Associates of St. Louis

    Florissant, Missouri

  • Sierra Eye Associates

    Reno, Nevada

  • NJ Retina

    Edison, New Jersey

  • Retina Associates of NJ

    Teaneck, New Jersey

  • Long Is. Vitreoretinal Consult

    Great Neck, New York

  • Ophthalmic Cons of Long Island

    Oceanside, New York

  • Retina Assoc of Western NY

    Rochester, New York

  • The Retina Consultants

    Slingerlands, New York

  • Retina Vit Surgeons/Central NY

    Syracuse, New York

  • Western Carolina Retinal Associate PA

    Asheville, North Carolina

  • Char Eye Ear &Throat Assoc

    Charlotte, North Carolina

  • Graystone Eye

    Hickory, North Carolina

  • Carolina Eye Associates

    Southern Pines, North Carolina

  • Cincinnati Eye Institute

    Cincinnati, Ohio

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.